Breaking News, Financial News

Financial Report: Lilly 2Q

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Lilly 2Q Revenues: $5.2 billion (+11%) 2Q Earnings: $958.8 million (+44%) YTD Revenues: $10.0 billion (+12%) YTD Earnings: $2.0 billion (+73%) Comments: Alimta, Byetta, Cialis, Cymbalta, Forteo, Strattera, Symbyax, Xigris and Yentreve, collectively grew 21% to $1.8 billion, and accounted for 35% of total sales, up from 32% in 2Q07. Zyprexa sales in the quarter were $1.2 billion (+2%). Cymbalta sales were $654.4 million (+26%). Gemzar sales were $440.1 million (+11%). Humalog sales...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters